A more than three-fold reduction in mortality in patients ≤70 years old; adjudicated neurological mortality reduced more than three-fold, and death from edema reduced 10-fold. 

Results Provide Additional Basis for Planned U.S. Phase 3 Trial in Large Hemispheric Stroke

Remedy Pharmaceuticals, a privately-held, phase 3-ready pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced additional efficacy data from its Phase 2 trial of CIRARA™ for preventing edema (brain swelling) in patients with large hemispheric stroke. The results were presented by the study’s two principal investigators, Kevin N. Sheth, MD of Yale University and W. Taylor Kimberly, MD of Massachusetts General Hospital, in two oral presentations during the International Stroke Conference (ISC) 2016, held February 17-19, 2016 at the Los Angeles Convention Center in Los Angeles, California.

Read the rest of story